Zymergen Inc. Lawsuit | Zymergen Inc. Losses
Zymergen, self-defined as “a science and material innovation company”, saw the value of its stock disappear just a few months after it went public. It is alleged that Zymergen was not transparent about its key product in the Registration Statement, a document that “must clearly describe important information about its business operations, financial condition, results of operations, risk factors, and management” (Securities and Exchange Commission). The company revealed on August 3 that its product – Hyaline – is facing technical issues. Revenues in 2021 and 2022 are most likely non-existent.
If you have invested in Zymergen, you may still recover your losses. Contact Peiffer Wolf today by filling out a Contact Form on our website or by calling 314-833-4825 to schedule a FREE Case Evaluation.
“A little more than three months after pricing its IPO at the top of its expected range and soaring out of the gate, Zymergen is warning investors that revenue from its experimental products won’t be coming anytime soon.” (CNBC)
Investors of Zymergen were shocked to learn that the value of the stocks they acquired when the company went public (in April) were almost 70% down on August 3. This was the result of a press release from Zymergen, which reads in part:
“Zymergen recently became aware of issues with its commercial product pipeline that will impact the Company’s delivery timeline and revenue projections. Accordingly, the Company no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.”
“During the quarter, several key target customers encountered technical issues in implementing Hyaline into their manufacturing processes typical of new product and process development learnings. The Company has made significant progress towards addressing these challenges and believes there are no intrinsic technical issues with Hyaline. However, this issue has resulted in a delay in the Company’s commercial ramp.”
Now, it is alleged that Zymergen’s Registration Statement, an essential document for companies going public, omitted the problems with Hyaline, which eventually caused the stock value to drop.
According to MarketWatch,
“Less than four months after going public and being valued at more than $3 billion by Wall Street, Zymergen Inc. unleashed some bad news Tuesday afternoon, and was on pace to lose more than two-thirds of its market cap.”
“Zymergen shares ZY, -13.81% plunged about 70% in after-hours trading Tuesday, after the “biofacturing” company revealed that its only current product is struggling in the market, a major target for future business isn’t panning out, and its chief executive is stepping down “by mutual decision.” After pricing its IPO at $31 a share on April 21, seeing shares move as high as $52 since, and closing Tuesday at $34.83, shares were trading for less than $10 in the extended session.”
“During the quarter, several key target customers encountered technical issues in implementing Hyaline into their manufacturing processes typical of new product and process development learnings. The Company has made significant progress towards addressing these challenges and believes there are no intrinsic technical issues with Hyaline. However, this issue has resulted in a delay in the Company’s commercial ramp.”
Have you suffered losses investing in Zymergen? The attorneys at Peiffer Wolf will fight to recover your losses.
While a rebound was on the news after the initial loss, Bloomberg alerted investors: “Despite the rebound, the stock is down more than 50% since going public at $31 a share.” Furthermore,
“Zymergen said it’s working to restore investor trust after customers were running into trouble getting its bioprocessed film meant for use in items like foldable smartphones implemented into their manufacturing processes. But skepticism has grown among Wall Street analysts. William Blair’s Matt Larew, who downgraded the stock to the equivalent of neutral, said its credibility was “destroyed.”
FREE Consultation | 314-833-4825
If you have invested in Zymergen, you may still recover your losses. Contact Peiffer Wolf today by filling out a Contact Form on our website or by calling 314-833-4825 to schedule a FREE Case Evaluation.
Yes. Please call us or use our contact form to request a Free Case Evaluation. We have a national team of attorneys and staff who look forward to speaking with you.
Typically, we represent clients on contingency fee agreements. If we take your case under a contingency fee arrangement, you won’t owe our firm any legal fees unless we are able to recover money for you.
Our contingency fee agreements are usually based on a percentage of the amount we recover for our clients. The contingency fee amount is determined by the type of case, our estimate of how long it will take to resolve your case, and our estimate of the litigation costs we will advance in your case. Each engagement agreement includes the details of the fee arrangement. Questions about our fee agreements are welcomed and encouraged.
In most litigation matters, it is extremely difficult – practically impossible – to predict how long it will take to resolve a particular case. Every case is different, and we will do our best to provide you with an estimate based on your case and our experience with similar cases. Moreover, we will do our best to keep you updated and manage expectations along the way.
We handle cases that change lives. Contact us today for a FREE consultation.
